The participants to be enrolled in this registry will be participants whose multiple myeloma has relapsed after the administration of 1 to 3 prior lines of therapy and who initiate treatment with a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments within 4 weeks prior to study enrollment. Participants are to be recruited from medical centers in the United States.